Osteosarcoma in Sprague-Dawley rats after long-term treatment with teriparatide (human parathyroid hormone (1-34))

Journal of Toxicological Sciences

Volumn 37, Issue 3, 2012, Pages 617-629

  Watanabe, Atsushi ^a   Yoneyama, Shigeki ^b   Nakajima, Mikio ^a   Sato, Norihiro ^a   Takao Kawabata, Ryoko ^a   Isogai, Yukihiro ^a   Sakurai Tanikawa, Aki ^a   Higuchi, Kazuhiro ^b   Shimo, Akihito ^b   Yamatoya, Hideyuki ^c   Yoshida, Kenji ^d   Kohira, Terutomo ^a  

^a ASAHI KASEI PHARMA CORPORATION   (Japan)

^b N   (Japan)

^c SHIN NIPPON BIOMEDICAL LABORATORIES LTD   (Japan)

^d SEKISUI CHEMICAL CO LTD   (Japan)

Author keywords

Carcinogenicity; Osteosarcoma; PTH; Sprague Dawley rat; Teriparatide

Indexed keywords

PARATHYROID HORMONE[1-34]; TERIBONE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE DENSITY; BONE MINERAL; CONTROLLED STUDY; CORTICAL BONE; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CARCINOGENICITY; DRUG INDUCED CANCER; EXTRAMEDULLARY HEMATOPOIESIS; FEMALE; FISCHER 344 RAT; LONG TERM CARE; MALE; NONHUMAN; OSTEOBLASTOMA; OSTEOSARCOMA; OSTEOSCLEROSIS; POST TREATMENT SURVIVAL; RAT; SPRAGUE DAWLEY RAT; TREATMENT DURATION;

RATTUS;

EID: 84863087584     PISSN: 03881350     EISSN: 18803989     Source Type: Journal    
DOI: 10.2131/jts.37.617     Document Type: Article

References (14)

1. Dawson, A.B. (1925): The age order of epiphyseal union in the long bones of the albino rat. Anat. Rec., 31, 1-17.
2. Dempster, D.W., Cosman, F., Parisien, M., Shen V. and Lindsay, R. (1993): Anabolic actions of parathyroid hormone on bone. Endocrine Rev., 14, 690-709.
3. Fox, J., Miller, M.A., Newman, M.K., Metcalfe, A.F., Turner, C.H., Recker, R.R. and Smith, S.Y. (2006): Daily treatment of aged ovariectomized rats with human parathyroid hormone (1-84) for 12 months reverses bone loss and enhances trabecular and cortical bone strength. Calcif. Tissue Int., 79, 262-272.
4. Fox, J., Miller, M.A., Newman, M.K., Turner, C.H., Recker, R.R. and Smith, S.Y. (2007): Treatment of skeletally mature ovariectomized rhesus monkeys with PTH(1-84) for 16 months increases bone formation and density and improves trabecular architecture and biomechanical properties at the lumbar spine. J. Bone Miner. Res., 22, 260-273.
5. Imai, K. and Yoshimura, S. (1988): Spontaneous tumors in Sprague-Dawley (CD:Crj) rats (in Japanese). J. Toxicol. Pathol., 1, 7-12.
6. Jolette, J., Wilker, C.E., Smith, S.Y., Doyle, N., Hardisty, J.F., Metcalfe, A.J., Marriott, T.B., Fox, J. and Wells, D.S. (2006): Defining a noncarcinogenic dose of recombinant human parathyroid hormone 1-84 in a 2-year study in Fischer 344 rats. Toxicol. Pathol., 34, 929-940.
7. MacKenzie, W.F. and Garner, F.M. (1973): Comparison of neoplasms in six sources of rats. J. Natl. Cancer Inst., 50, 1243-1257.
8. Nagayabu, T., Kandori, H., Miyoshi, H., Nishida, N., Kitasaki, T. and Sasaki, S. (2000): Crj:CD(SD)IGS rats and the effects of a commercial low protein diet in carcinogenicity studies at the drug safety research laboratories in takeda chemical industries, Ltd. In Biological reference data on CD(SD)IGS rats-2000 (Matsuzawa, T. and Inoue, H., eds.), pp.221-245, Charles River Japan, Inc., Yokohama.
9. Neer, R.M., Arnaud, C.D., Zanchetta, J.R., Prince, R., Gaich, G.A., Reginster, J.Y., Hodsman, A.B., Eriksen E.F., Ish-Shalom, S., Genant, H.K., Wang, O. and Mitlak, B.H. (2001): Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N. Engl. J. Med., 344, 1434-1441.
10. Saag, K.G., Shane, E., Boonen, S., Marín, F., Donley, D.W., Taylor, K.A., Dalsky, G.P. and Marcus, R. (2007): Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N. Engl. J. Med., 357, 2028-2039.
11. Sato, M., Vahle, J., Schmidt, A., Westmore, M., Smith, S., Rowley, E. and MA, L.Y. (2002): Abnormal bone architecture and biomechanical properties with near-lifetime treatment of rats with PTH. Endocrinology, 143, 3230-3242.
12. Sato, M., Westmore, M., Ma, Y.L., Schmidt, A., Zeng, Q.Q., Glass, E.V., Vahle, J., Brommage, R., Jerome, C.P. and Turner, C.H. (2004): Teriparatide [PTH(1-34)] strengthens the proximal femur of ovariectomized nonhuman primates despite increasing porosity. J. Bone Miner. Res., 19, 623-629.
13. Vahle, J.L., Sato, M., Long, G.G., Young, J.K., Francis, P.C., Engelhardt, J.A., Westmore, M.S., Ma, Y.L. and Nold, J.B. (2002): Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1-34) for 2 years and relevance to human safety. Toxicol. Pathol., 30, 312-321.
14. Vahle, J.L., Long, G.G., Sandusky, G., Westmore, M., Ma, Y.L. and Sato, M. (2004): Bone neoplasms in F344 rats given teriparatide [rhPTH(1-34)] are dependent on duration of treatment and dose. Toxicol. Pathol., 32, 426-438.